Milrinone
From Wikipedia, the free encyclopedia
 |
|
|
Milrinone
|
|
| Systematic (IUPAC) name | |
| 6-methyl-2-oxo-5-pyridin-4-yl-1H-pyridine-3-carbonitrile | |
| Identifiers | |
| CAS number | |
| ATC code | C01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C12H9N3O |
| Mol. mass | 211.219 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | 70 to 80% |
| Metabolism | ? |
| Half life | 2.3 hours |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Milrinone is a phosphodiesterase III inhibitor. It potentiates the effect of cyclic adenosine monophosphate (cAMP).
Milrinone also enhances relaxation of the left ventricle by increasing Ca2+-ATPase activity on the cardiac sarcoplasmic reticulum. This increases calcium ion uptake.
It has positive inotropic, vasodilating and minimal chronotropic effects. It is used in the management of heart failure only when conventional treatment with vasodilators and diuretics has proven insufficient. This is due to the potentially fatal adverse effects of milrinone, including ventricular arrhythmias.
Whereas beneficial hemodynamic (US English)/haemodynamic (British English) effects are shown (at least short-term), several studies have shown no or a negative effect on mortality rates of hospitalized patients receiving milrinone. And as such is beginning to be used more frequently in the critical and acute phases of cardiogenic shock.
One negative side to the use of milrinone is the prolonged half-life (2.5 hrs). This can result in a prolonged weaning and possible adverse outcomes from stopping this medication rapidly.
[edit] See also
[edit] External links
|
|
|
|---|---|
| PDE1 | Vinpocetine |
| PDE2 | EHNA |
| PDE3 | Amrinone, Bucladesine, Enoximone, Milrinone |
| PDE4 | Mesembrine, Rolipram |
| PDE5 | Sildenafil, Tadalafil, Vardenafil |
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
